The 10-second takeaway
For the quarter ended June 30 (Q1), Forest Laboratories beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share didn't move. GAAP earnings per share dropped significantly.
Gross margins increased, operating margins contracted, net margins dropped.
Forest Laboratories chalked up revenue of $832.9 million. The 14 analysts polled by S&P Capital IQ looked for sales of $808.7 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.28. The 20 earnings estimates compiled by S&P Capital IQ forecast $0.09 per share. Non-GAAP EPS of $0.28 were the same as the prior-year quarter. GAAP EPS of $0.09 for Q1 were 57% lower than the prior-year quarter's $0.21 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.1%, 70 basis points better than the prior-year quarter. Operating margin was 4.6%, 420 basis points worse than the prior-year quarter. Net margin was 2.8%, 400 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $841.6 million. On the bottom line, the average EPS estimate is $0.15.
Next year's average estimate for revenue is $3.46 billion. The average EPS estimate is $0.88.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Forest Laboratories is outperform, with an average price target of $39.05.
- Add Forest Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Anti-Depressants: The Secret to Preventing Alzheimer's?
Scientists are exploring the ways serotonin reuptake inhibitors might be able to slow Alzheimer's.
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Forest Laboratories bought Furiex Pharmaceuticals. Smart move?
Why Furiex Pharmaceuticals Inc. Shares Skyrocketed
Furiex shares soar after agreeing to be purchased by Forest Labs. Find out if this is a smart move or wasted money on Forest Labs' part.